Blend’s pipeline exemplifies the company’s productive R&D approach for developing first-in-class cancer drugs designed to overcome biologic barriers of cancer and improve the effectiveness of cancer therapies.
The lead drug candidates in Blend’s pipeline reflect two distinct innovations in cancer therapeutics:
- BTP-114 is a novel personalized cisplatin prodrug that is expected to enter the clinic in mid-2015.
- BTP-277 is the first of a series of Pentarins that Blend is developing based on its proprietary platform. Blend has obtained a robust preclinical proof-of-concept data package validating the promise of Pentarins as the next class of biologic drug conjugates.